FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124693358> ?p ?o ?g. }

• W2124693358 endingPage "340" @default.
• W2124693358 startingPage "332" @default.
• W2124693358 abstract "Background Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD. Methods One hundred thirty-one participants (sertraline = 67, placebo = 64) with mild-moderate AD and depression participated in the study. Patients who showed improvement on the modified Alzheimer's Disease Cooperative Study Clinical Global Impression-Change (mADCS-CGIC) after 12 weeks of randomized treatment with sertraline or placebo continued double-blinded treatment for an additional 12 weeks. Depression response and remission at 24 weeks were based on mADCS-CGIC score and change in Cornell Scale for Depression in Dementia (CSDD) score. Secondary outcome measures included time to remission, nonmood neuropsychiatric symptoms, global cognition, function, and quality of life. Results One hundred seventeen (89.3%) participants completed all study assessments and 74 (56.5%; sertraline = 38, placebo = 36) completed all 24 weeks on randomized treatment. By 24 weeks, there were no between-group differences in depression response (sertraline = 44.8%, placebo = 35.9%; odds ratio [95% CI] = 1.23 [0.64–2.35]), change in CSDD score (median difference = 0.6 [95% CI: −2.26 to 3.46], χ2 [df = 2] = 1.03), remission rates (sertraline = 32.8%, placebo = 21.8%; odds ratio [95% CI] = 1.61 [0.70–3.68]), or secondary outcomes. Common selective serotonin reuptake inhibitor-associated adverse events, specifically diarrhea, dizziness, and dry mouth, and pulmonary serious adverse events were more frequent in sertraline-randomized patients than in placebo subjects. Conclusions Sertraline treatment is not associated with delayed improvement between 12 and 24 weeks of treatment and may not be indicated for the treatment of depression of AD. Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD. One hundred thirty-one participants (sertraline = 67, placebo = 64) with mild-moderate AD and depression participated in the study. Patients who showed improvement on the modified Alzheimer's Disease Cooperative Study Clinical Global Impression-Change (mADCS-CGIC) after 12 weeks of randomized treatment with sertraline or placebo continued double-blinded treatment for an additional 12 weeks. Depression response and remission at 24 weeks were based on mADCS-CGIC score and change in Cornell Scale for Depression in Dementia (CSDD) score. Secondary outcome measures included time to remission, nonmood neuropsychiatric symptoms, global cognition, function, and quality of life. One hundred seventeen (89.3%) participants completed all study assessments and 74 (56.5%; sertraline = 38, placebo = 36) completed all 24 weeks on randomized treatment. By 24 weeks, there were no between-group differences in depression response (sertraline = 44.8%, placebo = 35.9%; odds ratio [95% CI] = 1.23 [0.64–2.35]), change in CSDD score (median difference = 0.6 [95% CI: −2.26 to 3.46], χ2 [df = 2] = 1.03), remission rates (sertraline = 32.8%, placebo = 21.8%; odds ratio [95% CI] = 1.61 [0.70–3.68]), or secondary outcomes. Common selective serotonin reuptake inhibitor-associated adverse events, specifically diarrhea, dizziness, and dry mouth, and pulmonary serious adverse events were more frequent in sertraline-randomized patients than in placebo subjects. Sertraline treatment is not associated with delayed improvement between 12 and 24 weeks of treatment and may not be indicated for the treatment of depression of AD." @default.
• W2124693358 created "2016-06-24" @default.
• W2124693358 creator A5024200262 @default.
• W2124693358 creator A5029408134 @default.
• W2124693358 creator A5033585095 @default.
• W2124693358 creator A5036700825 @default.
• W2124693358 creator A5037362183 @default.
• W2124693358 creator A5038707648 @default.
• W2124693358 creator A5039132019 @default.
• W2124693358 creator A5059020389 @default.
• W2124693358 creator A5061934117 @default.
• W2124693358 creator A5069682721 @default.
• W2124693358 creator A5073334486 @default.
• W2124693358 creator A5086330513 @default.
• W2124693358 date "2010-04-01" @default.
• W2124693358 modified "2023-10-17" @default.
• W2124693358 title "Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes" @default.
• W2124693358 cites W1164896577 @default.
• W2124693358 cites W168333064 @default.
• W2124693358 cites W1847168837 @default.
• W2124693358 cites W1989727902 @default.
• W2124693358 cites W1991517279 @default.
• W2124693358 cites W1996776294 @default.
• W2124693358 cites W2002330450 @default.
• W2124693358 cites W2008854521 @default.
• W2124693358 cites W2021166856 @default.
• W2124693358 cites W2035020452 @default.
• W2124693358 cites W2052496664 @default.
• W2124693358 cites W2058161128 @default.
• W2124693358 cites W2064616280 @default.
• W2124693358 cites W2070102177 @default.
• W2124693358 cites W2073448856 @default.
• W2124693358 cites W2084565575 @default.
• W2124693358 cites W2084782094 @default.
• W2124693358 cites W2089868121 @default.
• W2124693358 cites W2098690498 @default.
• W2124693358 cites W2111963393 @default.
• W2124693358 cites W2112549296 @default.
• W2124693358 cites W2139214514 @default.
• W2124693358 cites W2140121773 @default.
• W2124693358 cites W2148080316 @default.
• W2124693358 cites W2164303384 @default.
• W2124693358 cites W2167311298 @default.
• W2124693358 cites W2167951079 @default.
• W2124693358 cites W2193764494 @default.
• W2124693358 cites W2414690619 @default.
• W2124693358 cites W2595455140 @default.
• W2124693358 cites W4211101039 @default.
• W2124693358 cites W4229790659 @default.
• W2124693358 cites W4251901541 @default.
• W2124693358 cites W4376453734 @default.
• W2124693358 cites W6243660 @default.
• W2124693358 cites W64046613 @default.
• W2124693358 doi "https://doi.org/10.1097/jgp.0b013e3181cc0333" @default.
• W2124693358 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2849739" @default.
• W2124693358 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20220589" @default.
• W2124693358 hasPublicationYear "2010" @default.
• W2124693358 type Work @default.
• W2124693358 sameAs 2124693358 @default.
• W2124693358 citedByCount "160" @default.
• W2124693358 countsByYear W21246933582012 @default.
• W2124693358 countsByYear W21246933582013 @default.
• W2124693358 countsByYear W21246933582014 @default.
• W2124693358 countsByYear W21246933582015 @default.
• W2124693358 countsByYear W21246933582016 @default.
• W2124693358 countsByYear W21246933582017 @default.
• W2124693358 countsByYear W21246933582018 @default.
• W2124693358 countsByYear W21246933582019 @default.
• W2124693358 countsByYear W21246933582020 @default.
• W2124693358 countsByYear W21246933582021 @default.
• W2124693358 countsByYear W21246933582022 @default.
• W2124693358 countsByYear W21246933582023 @default.
• W2124693358 crossrefType "journal-article" @default.
• W2124693358 hasAuthorship W2124693358A5024200262 @default.
• W2124693358 hasAuthorship W2124693358A5029408134 @default.
• W2124693358 hasAuthorship W2124693358A5033585095 @default.
• W2124693358 hasAuthorship W2124693358A5036700825 @default.
• W2124693358 hasAuthorship W2124693358A5037362183 @default.
• W2124693358 hasAuthorship W2124693358A5038707648 @default.
• W2124693358 hasAuthorship W2124693358A5039132019 @default.
• W2124693358 hasAuthorship W2124693358A5059020389 @default.
• W2124693358 hasAuthorship W2124693358A5061934117 @default.
• W2124693358 hasAuthorship W2124693358A5069682721 @default.
• W2124693358 hasAuthorship W2124693358A5073334486 @default.
• W2124693358 hasAuthorship W2124693358A5086330513 @default.
• W2124693358 hasBestOaLocation W21246933582 @default.
• W2124693358 hasConcept C118552586 @default.
• W2124693358 hasConcept C126322002 @default.
• W2124693358 hasConcept C139719470 @default.
• W2124693358 hasConcept C142724271 @default.
• W2124693358 hasConcept C156957248 @default.
• W2124693358 hasConcept C15744967 @default.
• W2124693358 hasConcept C162324750 @default.
• W2124693358 hasConcept C168563851 @default.
• W2124693358 hasConcept C197934379 @default.
• W2124693358 hasConcept C204787440 @default.
• W2124693358 hasConcept C27081682 @default.
• W2124693358 hasConcept C2776000289 @default.

• next